Featured Publications

1. Abraham J. Monoclonal antibodies with extended half-life to prevent COVID-19. New England Journal of Medicine. 2022; 386:2236-2238 DOI: 10.1056/NEJMe2205563 (Editorial – Click on link to see video)

2. Xiong X, Tian S, Yang P, Lebreton F, Bao H, Sheng K, Yin L, Chen P, Zhang J, Qi W, Ruan J, Wu H, Chen H, Breault DT, Wu H, Earl AM, Gilmore MS**, Abraham J**, Dong M**. Emerging enterococcus pore-forming toxins with MHC/HLA-I as receptors. Cell. https://doi.org/10.1016/j.cell.2022.02.002.

3. Clark LE*, Clark SA*, Lin CY*, Liu J*, Coscia AC, Nabel KG, Yang P, Neel DV, Lee H, Brusic V, Stryapunina I, Plante KS, Ahmed AA, Catteruccia F, Young-Pearse TL, Chiu IM, Llopis PM, Weaver SC, Abraham J. (2021) VLDLR and ApoER2 are receptors for multiple alphaviruses. Nature. https://doi.org/10.1038/s41586-021-04326-0.

4. Nabel KG*, Clark S.A.*, Shankar S*, Pan J*, Clark L.E., Yang P, Coscia A, McKay L.G.A., Varnum HH, Brusic V, Tolan NV, Zhou G, Desjardins M, Turbett SE, Kanjilal S, Sherman AC, Dighe A, LaRocque RC, Ryan ET, Tylek C, Cohen-Solal JF, Darcy AT, Clabers A, Fan Y, Griffiths A, Correia IR, Seagal J, Baden LR, Charles RC, Abraham J. (2021) Structural basis for continued antibody evasion by the SARS-CoV-2 receptor-binding domain. Science. DOI: 10.1126/science.abl6251.

5. Sahtoe DD, Coscia A, Mustafaoglu N, Miller LM, Olal D, Vulovic I, Yu TY, Goreshnik I, Lin YR, Clark L, Busch F, Steward L, Wysocki VH, Ingber DE, Abraham J**, Baker D.** (2021) Transferrin receptor targeting by de novo sheet extension. PNAS.

5. Clark SA*, Clark LE*, Pan J*, Coscia A, McKay LGA, Shankar S, Johnson RI, Brusic V, Choudhary MC, Regan J, Li JZ, Griffiths A, Abraham J. (2021) SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell.  DOI:https://doi.org/10.1016/j.cell.2021.03.027

6. Koma T, Huang C, Coscia A, Hallam S, Manning JT, Maruyama J, Walker AG, Miller M, Smith JN, Patterson M, Abraham J, Paessler S. (2021) Glycoprotein N-linked glycans play a critical role in arenavirus pathogenicity. PLoS Pathogens (3):e1009356.

7. Abraham J.* (2020) Passive antibody therapy in COVID-19. Nature Reviews Immunology. https://doi.org/10.1038/s41577-020-0365-7

8. Clark LE, Mahmutovic S, Raymond DD, Dilanyan T, Koma T, Manning JT, Shankar S, Levis SC, Briggiler AM, Enria DA, Wucherpfennig KW, Paessler S, Abraham J*. (2018) Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. Nature Communications. 9,1884.

9. Gruszczyk J, Kanjee U, Chan LJ, Menant S, Malleret B, Lim NTY, Schmidt CQ, Mok YF, Lin KM, Pearson RD, Rangel G, Smith BJ, Call MJ, Weekes MP, Griffin MDW, Murphy JM, Abraham J, Sriprawat K, Menezes MJ, Ferreira MU, Russell B, Renia L, Duraisingh MT, Tham WH. (2018) Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax. Science. Jan; 359 (6371):48-55.

10. Mahmutovic S, Clark L, Levis SC, Briggiler AM, Enria DA, Harrison SC, Abraham J.* (2015) Molecular basis for antibody-mediated neutralization of New World hemorrhagic fever mammarenaviruses. Cell Host & Microbe. 18, 1-9.

11. Abraham J, Corbett KD, Farzan M, Choe H, Harrison SC. (2010) Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses. Nature Structural and Molecular Biology. Apr;17(4):438-444.

12. Radoshitzky SR*, Abraham J*, Spiropoulou CF, Kuhn JH, Nguyen D, Li W, Nagel J, Schmidt PJ, Nunberg JH, Andrews NC, Farzan M, Choe H. (2007) Transferrin receptor 1 is a cellular receptor for New World hemorrhagic fever arenaviruses. Nature. Mar 1;446(731):92-6.
* = Equal contribution